Skip to main content
Erschienen in: Anästhesie Nachrichten 4/2022

21.10.2022 | Freies Thema

Herzfrequenzkontrolle im Schock

verfasst von: Dr. med. Henning Lemm, Prof. Dr. med. Michael Buerke

Erschienen in: Anästhesie Nachrichten | Ausgabe 4/2022

Einloggen, um Zugang zu erhalten

Auszug

Das Herzminutenvolumen (HZV) stellt das Produkt von Schlagvolumen (SV) und Herzfrequenz (HR) dar. Aufgrund der physiologisch festgelegten relativ fixen Dauer der kardialen Systole ändert sich die Dauer der Diastole negativ proportional zur Herzfrequenz. Die für die Füllung des linken Ventrikels vorhandene Zeit sinkt somit mit steigender Herzfrequenz (Abb.  1).
Literatur
1.
Zurück zum Zitat Soma J, Aakhus S, Dahl K, Slørdahl S, Wiseth R, Widerøe TE (1996) Hemodynamics in white coat hypertension compared to ambulatory hypertension and normotension. Am J Hypertens 9:1090–1098 CrossRefPubMed Soma J, Aakhus S, Dahl K, Slørdahl S, Wiseth R, Widerøe TE (1996) Hemodynamics in white coat hypertension compared to ambulatory hypertension and normotension. Am J Hypertens 9:1090–1098 CrossRefPubMed
2.
Zurück zum Zitat Pierdomenico SD, Bucci A, Lapenna D, Cuccurullo F, Mezzetti A (2001) Clinic and ambulatory heart rate in sustained and white-coat hypertension. Blood Press Monit 6:239–244 CrossRefPubMed Pierdomenico SD, Bucci A, Lapenna D, Cuccurullo F, Mezzetti A (2001) Clinic and ambulatory heart rate in sustained and white-coat hypertension. Blood Press Monit 6:239–244 CrossRefPubMed
3.
Zurück zum Zitat Halliwill JR (2001) Mechanisms and clinical implications of post-exercise hypotension in humans. Exerc Sport Sci Rev 29:65–70 PubMed Halliwill JR (2001) Mechanisms and clinical implications of post-exercise hypotension in humans. Exerc Sport Sci Rev 29:65–70 PubMed
4.
Zurück zum Zitat Izzo JL, Anwar MA, Elango K, Ahmed R, Osmond P (2019) Decoupling of heart rate and blood pressure: hemodynamic counter-regulatory mechanisms and their implications. Artery Res 25:87–94 CrossRef Izzo JL, Anwar MA, Elango K, Ahmed R, Osmond P (2019) Decoupling of heart rate and blood pressure: hemodynamic counter-regulatory mechanisms and their implications. Artery Res 25:87–94 CrossRef
6.
Zurück zum Zitat Berk JL, Hagen JF, Maly G, Koo R (1972) The treatment of shock with beta adrenergic blockade. Arch Surg 104:46–51 CrossRefPubMed Berk JL, Hagen JF, Maly G, Koo R (1972) The treatment of shock with beta adrenergic blockade. Arch Surg 104:46–51 CrossRefPubMed
7.
Zurück zum Zitat Benedict CR, Rose JA (1992) Arterial norepinephrine changes in patients with septic shock. Circ Shock 38:165–172 PubMed Benedict CR, Rose JA (1992) Arterial norepinephrine changes in patients with septic shock. Circ Shock 38:165–172 PubMed
8.
Zurück zum Zitat Sander O, Welters ID, Foëx P, Sear JW (2005) Impact of prolonged elevated heart rate on incidence of major cardiac events in critically ill patients with a high risk of cardiac complications. Crit Care Med 33:81–88 (discussion 241–242) CrossRefPubMed Sander O, Welters ID, Foëx P, Sear JW (2005) Impact of prolonged elevated heart rate on incidence of major cardiac events in critically ill patients with a high risk of cardiac complications. Crit Care Med 33:81–88 (discussion 241–242) CrossRefPubMed
9.
Zurück zum Zitat Schmittinger CA, Torgersen C, Luckner G, Schröder DCH, Lorenz I, Dünser MW (2012) Adverse cardiac events during catecholamine vasopressor therapy: a prospective observational study. Intensive Care Med 38:950–958 CrossRefPubMed Schmittinger CA, Torgersen C, Luckner G, Schröder DCH, Lorenz I, Dünser MW (2012) Adverse cardiac events during catecholamine vasopressor therapy: a prospective observational study. Intensive Care Med 38:950–958 CrossRefPubMed
10.
Zurück zum Zitat Morelli A, Ertmer C, Westphal M et al (2013) Effect of heart rate control with esmolol on hemodynamic and clinical outcomes in patients with septic shock: a randomized clinical trial. JAMA 310:1683–1691 CrossRefPubMed Morelli A, Ertmer C, Westphal M et al (2013) Effect of heart rate control with esmolol on hemodynamic and clinical outcomes in patients with septic shock: a randomized clinical trial. JAMA 310:1683–1691 CrossRefPubMed
11.
Zurück zum Zitat Fuchs C, Wauschkuhn S, Scheer C, Vollmer M, Meissner K, Kuhn S‑O, Hahnenkamp K, Morelli A, Gründling M, Rehberg S (2017) Continuing chronic beta-blockade in the acute phase of severe sepsis and septic shock is associated with decreased mortality rates up to 90 days. Br J Anaesth 119:616–625 CrossRefPubMed Fuchs C, Wauschkuhn S, Scheer C, Vollmer M, Meissner K, Kuhn S‑O, Hahnenkamp K, Morelli A, Gründling M, Rehberg S (2017) Continuing chronic beta-blockade in the acute phase of severe sepsis and septic shock is associated with decreased mortality rates up to 90 days. Br J Anaesth 119:616–625 CrossRefPubMed
12.
Zurück zum Zitat Hennen R, Friedrich I, Hoyer D et al (2008) Autonome Dysfunktion und Betablocker beim Multiorgandysfunktionssyndrom. Dtsch Med Wochenschr 133:2500–2504 CrossRefPubMed Hennen R, Friedrich I, Hoyer D et al (2008) Autonome Dysfunktion und Betablocker beim Multiorgandysfunktionssyndrom. Dtsch Med Wochenschr 133:2500–2504 CrossRefPubMed
13.
Zurück zum Zitat Schmidt H, Müller-Werdan U, Hoffmann T et al (2006) Attenuated autonomic function in multiple organ dysfunction syndrome across three age groups. Biomed Tech 51:264–267 CrossRef Schmidt H, Müller-Werdan U, Hoffmann T et al (2006) Attenuated autonomic function in multiple organ dysfunction syndrome across three age groups. Biomed Tech 51:264–267 CrossRef
14.
Zurück zum Zitat Schmidt H, Lotze U, Ghanem A et al (2014) Relation of impaired interorgan communication and parasympathetic activity in chronic heart failure and multiple-organ dysfunction syndrome. J Crit Care 29:367–373 CrossRefPubMed Schmidt H, Lotze U, Ghanem A et al (2014) Relation of impaired interorgan communication and parasympathetic activity in chronic heart failure and multiple-organ dysfunction syndrome. J Crit Care 29:367–373 CrossRefPubMed
15.
Zurück zum Zitat Domanovits H, Wolzt M, Stix G (2018) Landiolol: pharmacology and its use for rate control in atrial fibrillation in an emergency setting. Eur Heart J Suppl 20:A1–A3 CrossRefPubMedPubMedCentral Domanovits H, Wolzt M, Stix G (2018) Landiolol: pharmacology and its use for rate control in atrial fibrillation in an emergency setting. Eur Heart J Suppl 20:A1–A3 CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Matsuda N, Nishida O, Taniguchi T et al (2020) Impact of patient characteristics on the efficacy and safety of landiolol in patients with sepsis-related tachyarrhythmia: Subanalysis of the J‑Land 3S randomised controlled study. EClinicalMedicine 28:100571 CrossRefPubMedPubMedCentral Matsuda N, Nishida O, Taniguchi T et al (2020) Impact of patient characteristics on the efficacy and safety of landiolol in patients with sepsis-related tachyarrhythmia: Subanalysis of the J‑Land 3S randomised controlled study. EClinicalMedicine 28:100571 CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Kakihana Y, Nishida O, Taniguchi T, Okajima M, Morimatsu H, Ogura H, Yamada Y, Nagano T, Morishima E, Matsuda N (2020) Efficacy and safety of landiolol, an ultra-short-acting β1-selective antagonist, for treatment of sepsis-related tachyarrhythmia (J-Land 3S): a multicentre, open-label, randomised controlled trial. Lancet Respir Med 8:863–872 CrossRefPubMed Kakihana Y, Nishida O, Taniguchi T, Okajima M, Morimatsu H, Ogura H, Yamada Y, Nagano T, Morishima E, Matsuda N (2020) Efficacy and safety of landiolol, an ultra-short-acting β1-selective antagonist, for treatment of sepsis-related tachyarrhythmia (J-Land 3S): a multicentre, open-label, randomised controlled trial. Lancet Respir Med 8:863–872 CrossRefPubMed
18.
Zurück zum Zitat Hasegawa D, Sato R, Prasitlumkum N, Nishida K, Takahashi K, Yatabe T, Nishida O (2021) Effect of ultrashort-acting β‑blockers on mortality in patients with sepsis with persistent tachycardia despite initial resuscitation: a systematic review and meta-analysis of randomized controlled trials. Chest 159:2289–2300 CrossRefPubMed Hasegawa D, Sato R, Prasitlumkum N, Nishida K, Takahashi K, Yatabe T, Nishida O (2021) Effect of ultrashort-acting β‑blockers on mortality in patients with sepsis with persistent tachycardia despite initial resuscitation: a systematic review and meta-analysis of randomized controlled trials. Chest 159:2289–2300 CrossRefPubMed
19.
Zurück zum Zitat Plosker GL (2013) Landiolol: a review of its use in Intraoperative and postoperative tachyarrhythmias. Drugs 73:959–977 CrossRefPubMed Plosker GL (2013) Landiolol: a review of its use in Intraoperative and postoperative tachyarrhythmias. Drugs 73:959–977 CrossRefPubMed
20.
Zurück zum Zitat Levy B, Fritz C, Piona C, Duarte K, Morelli A, Guerci P, Kimmoun A, Girerd N (2021) Hemodynamic and anti-inflammatory effects of early esmolol use in hyperkinetic septic shock: a pilot study. Crit Care 25:21 CrossRefPubMedPubMedCentral Levy B, Fritz C, Piona C, Duarte K, Morelli A, Guerci P, Kimmoun A, Girerd N (2021) Hemodynamic and anti-inflammatory effects of early esmolol use in hyperkinetic septic shock: a pilot study. Crit Care 25:21 CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat Bosch NA, Rucci JM, Massaro JM, Winter MR, Quinn EK, Chon KH, McManus DD, Walkey AJ (2021) Comparative Effectiveness of Heart Rate Control Medications for the Treatment of Sepsis-Associated Atrial Fibrillation. Chest 159:1452–1459 CrossRefPubMed Bosch NA, Rucci JM, Massaro JM, Winter MR, Quinn EK, Chon KH, McManus DD, Walkey AJ (2021) Comparative Effectiveness of Heart Rate Control Medications for the Treatment of Sepsis-Associated Atrial Fibrillation. Chest 159:1452–1459 CrossRefPubMed
23.
Zurück zum Zitat Izco PM, Castejón B, Piedras MJ, Zamorano JL, Sanmartín M, Zaragoza C (2017) Effects of Ivabradine on heart rate and Hemodynamic parameters in a swine model of cardiogenic shock. Rev Esp Cardiol (Engl Ed) 70:1139–1141 Izco PM, Castejón B, Piedras MJ, Zamorano JL, Sanmartín M, Zaragoza C (2017) Effects of Ivabradine on heart rate and Hemodynamic parameters in a swine model of cardiogenic shock. Rev Esp Cardiol (Engl Ed) 70:1139–1141
24.
Zurück zum Zitat Nuding S, Schröder J, Presek P, Wienke A, Müller-Werdan U, Ebelt H, Werdan K (2018) Reducing elevated heart rates in patients with multiple organ dysfunction syndrome with the if (funny channel current) inhibitor Ivabradine. Shock 49:402–411 CrossRefPubMed Nuding S, Schröder J, Presek P, Wienke A, Müller-Werdan U, Ebelt H, Werdan K (2018) Reducing elevated heart rates in patients with multiple organ dysfunction syndrome with the if (funny channel current) inhibitor Ivabradine. Shock 49:402–411 CrossRefPubMed
25.
Zurück zum Zitat Barillà F, Pannarale G, Torromeo C et al (2016) Ivabradine in patients with ST-elevation myocardial infarction complicated by cardiogenic shock: a preliminary randomized prospective study. Clin Drug Investig 36:849–856 CrossRefPubMed Barillà F, Pannarale G, Torromeo C et al (2016) Ivabradine in patients with ST-elevation myocardial infarction complicated by cardiogenic shock: a preliminary randomized prospective study. Clin Drug Investig 36:849–856 CrossRefPubMed
26.
Zurück zum Zitat Werdan K, Boeken U, Briegel MJ et al (2021) Short version of the 2nd edition of the German-Austrian S3 guidelines “Cardiogenic shock complicating myocardial infarction-Diagnosis, monitoring and treatment”. Anaesthesist 70:42–70 CrossRefPubMed Werdan K, Boeken U, Briegel MJ et al (2021) Short version of the 2nd edition of the German-Austrian S3 guidelines “Cardiogenic shock complicating myocardial infarction-Diagnosis, monitoring and treatment”. Anaesthesist 70:42–70 CrossRefPubMed
Metadaten
Titel
Herzfrequenzkontrolle im Schock
verfasst von
Dr. med. Henning Lemm
Prof. Dr. med. Michael Buerke
Publikationsdatum
21.10.2022
Verlag
Springer Vienna
Erschienen in
Anästhesie Nachrichten / Ausgabe 4/2022
Print ISSN: 2617-2127
Elektronische ISSN: 2731-3972
DOI
https://doi.org/10.1007/s44179-022-00098-8

Weitere Artikel der Ausgabe 4/2022

Anästhesie Nachrichten 4/2022 Zur Ausgabe

UPDATE Österreichische Palliativgesellschaft

OPG-Update

Der interessante Fall

Das Unterdrucklungenödem